Vertex Pharmaceuticals (VRTX) announced that the European Commission has granted approval for Alyftrek for the treatment of people with cystic fibrosis ages six years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator gene.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Cautious Hold Rating for Vertex Pharmaceuticals Amid Limited Uptake and Insurance Challenges for Journavx
- Cautious Hold Rating on Vertex Pharmaceuticals Amid Promising Diabetes Treatment and Market Uncertainties
- Hold Rating on Vertex Pharmaceuticals: Balancing Promising Efficacy with Scalability and Commercial Viability Concerns for Zimislecel Therapy
- Vertex Pharmaceuticals’ Zimislecel Shows Promising Advances in Type 1 Diabetes Treatment, Earning a Buy Rating
- Vertex, Ono announce license agreement for povetacicept in Japan and South Korea